INNO:CSE, InnoCan Pharma Corporation
INNO stock overview
InnoCan Pharma Corporation (INNO:CSE) closed at $1.90 on October 15, 2026,
unchanged on the day.
The stock trades 90.1% below its 52-week high of $19.15
and 18.8% above its 52-week low of $1.60.
Over the past year, it lost 88.8%.
InnoCan Pharma Corporation is part of the Life Sciences sector.
Key figures
- Price
- $1.90
- Day change
- 0.00%
- Volume
- 0
- Average volume
- 1,769
- Market cap
- 8M+
- 52-week range
- $1.60 – $19.15
- 50-day average
- $2.16
- 200-day average
- $4.50
Price action over the past year
In 252 trading sessions since October 24, 2025, INNO closed higher on 49 days (19%).
Its best day was July 3, 2026 (+45.83%) and its worst was July 28, 2026 (-26.10%).
The stock moved 10% or more in a single session 32 times.
It opened at least 5% above the previous day's high 14 times.
Recent signals
INNO news
-
Oct 23, 2026:
Is Summit Hotel Properties (INN) Stock Undervalued Right Now?
-
Oct 23, 2026:
Summit Hotel Properties, Inc. (INN) Hit a 52 Week High, Can the Run Continue?
-
Oct 22, 2026:
Sunstone Hotel Investors, Inc. (SHO) Hits Fresh High: Is There Still Room to Run?
-
Oct 8, 2026:
VALITIC™ Launches Direct-to-Consumer Website, Laying Groundwork for U.S. Holiday Campaign
-
Oct 7, 2026:
Is Summit Hotel Properties (INN) a Great Value Stock Right Now?
-
Oct 1, 2026:
VALITIC™ Featured by BuzzFeed for "Magical Results," Further Strengthening Consumer Brand Momentum
-
Sep 29, 2026:
VALITIC™ Expands Retail Industry Visibility Through Shoptalk Fall 2026 in Nashville, USA
-
Sep 23, 2026:
SUMMIT HOTEL PROPERTIES ANNOUNCES THIRD QUARTER 2026 EARNINGS RELEASE DATE
About InnoCan Pharma Corporation
InnoCan Pharma Corp is a Canada based company engaged in the research, development, marketing, distribution and sales of InnoCan-branded OTC pharmaceutical products. Its brands include Shir and Relief & Go.
Similar stocks
Find more stocks like INNO with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.